Vaxcyte (PCVX) Interest Expenses (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Interest Expenses of $3.7 million for Q1 2026, up 20.2% year-over-year from $3.1 million in Q1 2025, and down 97.16% quarter-over-quarter from $130.4 million in Q4 2025.
Vaxcyte (PCVX) Interest Expenses (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Interest Expenses for 8 consecutive years, with $3.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 20.2% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at -$1.6 million (up 69.65% YoY), while the FY2025 annual figure was $645.3 million, up 44.66% from the prior year.
- Interest Expenses declined to $3.7 million in Q1 2026 per PCVX's latest filing, from $130.4 million in the prior quarter.
- Across five years, Interest Expenses topped out at $363.1 million in Q1 2024 and bottomed at -$8.4 million in Q4 2024.
- Historically, Interest Expenses has averaged $106.6 million across 5 years, with a median of $78.8 million in 2022.
- On a YoY basis, Interest Expenses climbed as much as 3165.83% in 2025 and fell as far as 99.15% in 2025.
- Vaxcyte's Interest Expenses stood at $74.1 million in 2022, then soared by 235.74% to $248.9 million in 2023, then tumbled by 103.38% to -$8.4 million in 2024, then surged by 1650.69% to $130.4 million in 2025, then plunged by 97.16% to $3.7 million in 2026.
- Business Quant data shows PCVX's Interest Expenses at $3.7 million in Q1 2026, $130.4 million in Q4 2025, and $118.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | 200.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 200.93 Mn |
| Jun 30, 2026 | 200.93 Mn |
| Mar 31, 2026 | 3.71 Mn |
| Mar 31, 2026 | 3.71 Mn |
| Dec 31, 2025 | 130.35 Mn |
| Dec 31, 2025 | 130.35 Mn |
| Sep 30, 2025 | 118.03 Mn |
| Sep 30, 2025 | 118.03 Mn |
| Jun 30, 2025 | 120.97 Mn |
| Jun 30, 2025 | 120.97 Mn |
| Mar 31, 2025 | 3.08 Mn |
| Mar 31, 2025 | 3.08 Mn |
| Dec 31, 2024 | -8.41 Mn |
| Dec 31, 2024 | -8.41 Mn |
| Sep 30, 2024 | 3.61 Mn |
| Sep 30, 2024 | 3.61 Mn |
| Jun 30, 2024 | 4.78 Mn |
| Jun 30, 2024 | 4.78 Mn |
| Mar 31, 2024 | 363.13 Mn |
| Mar 31, 2024 | 363.13 Mn |